BCL2 and acute myeloid leukemia: The basic treatment of AML patients involves an induction chemotherapy regimen (7 + 3 regimen), followed by consolidation chemotherapy and/or allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with a high risk of relapse: For older or unfit patients, an alternative treatment is usually adopted based on the administration of azacitidine or hypomethylating agents, in combination with Venetoclax, targeting the anti-apoptotic protein Bcl-2.